CleanAir Engineering's Partnerships

Clean Air Engineering works closely with a number of other companies and organizations in order to provide a comprehensive range of services. These companies and a brief description of their services are provided below.

MAAMEL-logoThe National Laboratory Company LTD. (MAAMEL) is a limited liability company under the corporate laws of the Kingdom of Saudi Arabia. The company is specialized in the area of investment in sophisticated laboratory analytical services. Maamel represents a family of companies such as ALS Arabia which is a joint venture with ALS Laboratories of Australia providing high quality analytical services and Arensco, a wholly owned subsidy, providing ambient air and industrial hygiene monitoring.

cae_logoCleanAir Europe is a company orginized under the corporate laws of France. CleanAir Europe is owned by Clean Air Engineering, Inc. (CleanAir®).

caa-logoCleanAir Arabia is a limited liability company under the corporate laws of the Kingdom of Saudi Arabia. The company is specialized in the area of environmental measurement. CleanAir Arabia is jointly owned by Clean Air Engineering, Inc (CleanAir®) and National Laboratory Company LTD. (MAAMEL).

Donate to CleanAir® and become one of our partners in the fight for global sustainability.


CleanAir Position on Government Competition


Our Position Statement:

CleanAir is dedicated to defending the private-sector right to free and fair markets. We will vigorously oppose all taxpayer-subsidized competition by any and all government agencies competing with the private sector.  CleanAir believes in the principles of free enterprise and limited government that have fostered our nation's economic development since its founding.  CleanAir will use all means available to get any and all government agencies to immediately stop and desist activities which can be provided by private companies.

Our Commitments:        

CleanAir will help to forge a partnership between organizations interested in limiting government constraint of trade. CleanAir will support government initiatives to transfer work to the private sector.

CleanAir will work with like minded companies to help ensure smooth operations of private industry. It is our desire to create programs which can be used as models for public-private alliances between industry and government.

Our Methods:    

Often government agencies fund other government-owned entities to do research which is needed for the greater good and which is not being addressed by private or public companies. This concept sounds good to politicians and their constituents, but what is the return on all of these government funded projects? We believe if we are to continue to support governments doing research and commercial work then there needs to be annual accountability for each, including:

        • Monitary value, for each project, of the "greater good" that will be created if the work succeeds. This should be revisited annually using independent review by a related trade association. If more than one trade association claims interest the review should rotate. Reviewer will be compensated at a rate of 1% of annual funding.

        • Independent analysis of the possibility of success.

        • Annual determination if the private sector is ready and able to perform this work. If not, is another government agency better able to do it?

        • List of every project completed by this government organization in the last 25 years and benefits achieved. For successes provide Internet links to all directly related sites to prove each project is still providing benefit.

        • Summary of the contribution to the greater good by every project success for all projects funded over the last 25 years.

        • Analysis of who received the benefits created including organizations, regions and population groups.

It is easy to say all the government  Health, Safety and Environmental investments funded by tax dollars over the last 50 years saved trillions in medical costs and extended life expectancy for any country, but it is hard to prove using data on health insurance costs, pharmaceutical sales, and life expectancy.